Tianjin Medical Journal ›› 2022, Vol. 50 ›› Issue (10): 1009-1013.doi: 10.11958/20220599
• Cell and Molecular Biology • Next Articles
LIN Haipeng, DANG Xuhong, ZUO Yahui
Received:
2022-04-22
Revised:
2022-06-09
Published:
2022-10-15
Online:
2022-10-20
LIN Haipeng, DANG Xuhong, ZUO Yahui. Effects of substance P on the secretory function and the expression of endogenous VEGF, bFGF and PDGF in radiation-injured skin fibroblasts[J]. Tianjin Medical Journal, 2022, 50(10): 1009-1013.
CLC Number:
基因名称 | 引物序列(5'→3') | 产物大小(bp) |
---|---|---|
VEGF | 上游:CGAGACCCTGGTGGACATCTT | 180 |
下游:TGGCCTTGGTGAGGTTTGATC | ||
bFGF | 上游:AGAAGAGCGACCCTCACATCA | 226 |
下游:CGTTTCAGTGCCACATACCAA | ||
PDGF | 上游:ACCAGGACGGTCATTTACGA | 136 |
下游:AGGGCTGGCACTTGACACT | ||
GAPDH | 上游:TGGGTGTGAACCATGAGAAGT | 126 |
下游:TGAGTCCTTCCACGATACCAA |
Tab. 1 Design of real-time fluorescence quantitative PCR primers
基因名称 | 引物序列(5'→3') | 产物大小(bp) |
---|---|---|
VEGF | 上游:CGAGACCCTGGTGGACATCTT | 180 |
下游:TGGCCTTGGTGAGGTTTGATC | ||
bFGF | 上游:AGAAGAGCGACCCTCACATCA | 226 |
下游:CGTTTCAGTGCCACATACCAA | ||
PDGF | 上游:ACCAGGACGGTCATTTACGA | 136 |
下游:AGGGCTGGCACTTGACACT | ||
GAPDH | 上游:TGGGTGTGAACCATGAGAAGT | 126 |
下游:TGAGTCCTTCCACGATACCAA |
组别 | Col-Ⅰ (μg/L) | Col-Ⅲ (μg/L) | Col-Ⅰ/ Col-Ⅲ | CGRP (ng/L) |
---|---|---|---|---|
0 Gy组 | 14.34±0.25 | 31.50±0.69 | 0.46±0.02 | 52.48±2.04 |
2 Gy组 | 20.50±0.19a | 30.14±0.35 | 0.68±0.01a | 53.07±3.50 |
6 Gy组 | 19.31±0.51a | 32.52±1.18 | 0.59±0.03a | 61.48±1.86a |
12 Gy组 | 21.07±0.84a | 33.37±0.74a | 0.63±0.02a | 99.91±4.94a |
18 Gy组 | 26.33±0.63a | 33.50±0.74a | 0.79±0.03a | 103.80±2.82a |
0 Gy+SP组 | 21.86±0.93a | 28.16±1.26a | 0.78±0.01a | 62.57±4.17a |
2 Gy+SP组 | 18.22±0.63b | 31.97±0.57b | 0.57±0.01b | 76.89±4.11b |
6 Gy+SP组 | 16.10±0.57c | 33.35±1.01 | 0.48±0.03c | 98.92±2.78c |
12 Gy+SP组 | 23.31±1.25d | 42.24±1.15d | 0.55±0.02d | 102.29±3.64 |
18 Gy+SP组 | 25.07±0.99 | 41.37±0.74e | 0.61±0.02e | 108.88±3.13 |
F | 76.684** | 77.852** | 80.440** | 135.039** |
Tab. 2 Comparison of expression levels of Col-Ⅰ, Col-Ⅲ, Col-Ⅰ/Col-Ⅲ and CGRP between different culture medium groups
组别 | Col-Ⅰ (μg/L) | Col-Ⅲ (μg/L) | Col-Ⅰ/ Col-Ⅲ | CGRP (ng/L) |
---|---|---|---|---|
0 Gy组 | 14.34±0.25 | 31.50±0.69 | 0.46±0.02 | 52.48±2.04 |
2 Gy组 | 20.50±0.19a | 30.14±0.35 | 0.68±0.01a | 53.07±3.50 |
6 Gy组 | 19.31±0.51a | 32.52±1.18 | 0.59±0.03a | 61.48±1.86a |
12 Gy组 | 21.07±0.84a | 33.37±0.74a | 0.63±0.02a | 99.91±4.94a |
18 Gy组 | 26.33±0.63a | 33.50±0.74a | 0.79±0.03a | 103.80±2.82a |
0 Gy+SP组 | 21.86±0.93a | 28.16±1.26a | 0.78±0.01a | 62.57±4.17a |
2 Gy+SP组 | 18.22±0.63b | 31.97±0.57b | 0.57±0.01b | 76.89±4.11b |
6 Gy+SP组 | 16.10±0.57c | 33.35±1.01 | 0.48±0.03c | 98.92±2.78c |
12 Gy+SP组 | 23.31±1.25d | 42.24±1.15d | 0.55±0.02d | 102.29±3.64 |
18 Gy+SP组 | 25.07±0.99 | 41.37±0.74e | 0.61±0.02e | 108.88±3.13 |
F | 76.684** | 77.852** | 80.440** | 135.039** |
组别 | Col-Ⅰ (μg/L) | Col-Ⅲ (μg/L) | Col-Ⅰ/ Col-Ⅲ | CGRP (ng/L) |
---|---|---|---|---|
0 Gy组 | 38.78±0.53 | 73.59±0.66 | 0.53±0.01 | 26.56±0.61 |
2 Gy组 | 39.10±0.62 | 72.29±0.90 | 0.54±0.01 | 33.53±0.71a |
6 Gy组 | 42.98±1.28a | 78.70±1.94a | 0.55±0.00 | 31.10±0.58a |
12 Gy组 | 39.69±1.12 | 72.84±0.62 | 0.54±0.02 | 32.55±0.73a |
18 Gy组 | 43.86±0.71a | 78.05±1.83a | 0.56±0.01a | 31.48±0.09a |
0 Gy+SP组 | 37.81±0.49 | 72.13±0.90 | 0.52±0.01 | 29.52±1.25a |
2 Gy+SP组 | 33.64±0.42b | 65.40±1.88b | 0.51±0.02b | 28.81±0.41b |
6 Gy+SP组 | 37.25±0.31c | 79.14±1.70 | 0.47±0.01c | 32.70±0.96c |
12 Gy+SP组 | 38.19±0.37d | 68.44±0.77d | 0.56±0.01 | 31.07±0.95d |
18 Gy+SP组 | 37.19±0.44e | 70.83±0.84e | 0.53±0.00e | 38.15±0.58e |
F | 52.361** | 34.876** | 14.151** | 51.309** |
Tab. 3 Comparison of the expression levels of endogenous Col-Ⅰ, Col-Ⅲ, Col-Ⅰ/Col-Ⅲ and CGRP between the ten groups
组别 | Col-Ⅰ (μg/L) | Col-Ⅲ (μg/L) | Col-Ⅰ/ Col-Ⅲ | CGRP (ng/L) |
---|---|---|---|---|
0 Gy组 | 38.78±0.53 | 73.59±0.66 | 0.53±0.01 | 26.56±0.61 |
2 Gy组 | 39.10±0.62 | 72.29±0.90 | 0.54±0.01 | 33.53±0.71a |
6 Gy组 | 42.98±1.28a | 78.70±1.94a | 0.55±0.00 | 31.10±0.58a |
12 Gy组 | 39.69±1.12 | 72.84±0.62 | 0.54±0.02 | 32.55±0.73a |
18 Gy组 | 43.86±0.71a | 78.05±1.83a | 0.56±0.01a | 31.48±0.09a |
0 Gy+SP组 | 37.81±0.49 | 72.13±0.90 | 0.52±0.01 | 29.52±1.25a |
2 Gy+SP组 | 33.64±0.42b | 65.40±1.88b | 0.51±0.02b | 28.81±0.41b |
6 Gy+SP组 | 37.25±0.31c | 79.14±1.70 | 0.47±0.01c | 32.70±0.96c |
12 Gy+SP组 | 38.19±0.37d | 68.44±0.77d | 0.56±0.01 | 31.07±0.95d |
18 Gy+SP组 | 37.19±0.44e | 70.83±0.84e | 0.53±0.00e | 38.15±0.58e |
F | 52.361** | 34.876** | 14.151** | 51.309** |
组别 | VEGF mRNA | bFGF mRNA | PDGF mRNA |
---|---|---|---|
0 Gy组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
2 Gy组 | 0.75±0.04a | 1.12±0.11 | 1.31±0.06 |
6 Gy组 | 1.13±0.10 | 1.70±0.44a | 1.62±0.16a |
12 Gy组 | 1.09±0.12 | 1.51±0.28a | 1.80±0.20a |
18 Gy组 | 1.03±0.03 | 1.65±0.33a | 1.90±0.09a |
0 Gy+SP组 | 1.64±0.16a | 1.55±0.15a | 1.57±0.14a |
2 Gy+SP组 | 1.28±0.04b | 1.65±0.09b | 1.57±0.17 |
6 Gy+SP组 | 0.86±0.04c | 1.55±0.39 | 1.54±0.37 |
12 Gy+SP组 | 2.31±0.01d | 1.98±0.04d | 2.45±0.45d |
18 Gy+SP组 | 2.14±0.22e | 2.62±0.32e | 2.42±0.27e |
F | 81.916** | 8.663** | 11.405** |
Tab. 4 Comparison of mRNA expression levels of VEGF, bFGF and PDGF between the ten groups
组别 | VEGF mRNA | bFGF mRNA | PDGF mRNA |
---|---|---|---|
0 Gy组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
2 Gy组 | 0.75±0.04a | 1.12±0.11 | 1.31±0.06 |
6 Gy组 | 1.13±0.10 | 1.70±0.44a | 1.62±0.16a |
12 Gy组 | 1.09±0.12 | 1.51±0.28a | 1.80±0.20a |
18 Gy组 | 1.03±0.03 | 1.65±0.33a | 1.90±0.09a |
0 Gy+SP组 | 1.64±0.16a | 1.55±0.15a | 1.57±0.14a |
2 Gy+SP组 | 1.28±0.04b | 1.65±0.09b | 1.57±0.17 |
6 Gy+SP组 | 0.86±0.04c | 1.55±0.39 | 1.54±0.37 |
12 Gy+SP组 | 2.31±0.01d | 1.98±0.04d | 2.45±0.45d |
18 Gy+SP组 | 2.14±0.22e | 2.62±0.32e | 2.42±0.27e |
F | 81.916** | 8.663** | 11.405** |
组别 | VEGF | bFGF | PDGF |
---|---|---|---|
0 Gy组 | 788.84±41.15 | 24.92±0.28 | 12.02±0.21 |
2 Gy组 | 856.82±24.47a | 26.90±0.59a | 12.50±0.40a |
6 Gy组 | 954.71±23.71a | 24.75±0.28 | 11.74±0.19 |
12 Gy组 | 1 090.68±15.14a | 25.93±0.27a | 12.18±0.22 |
18 Gy组 | 1 140.53±24.67a | 26.92±0.94a | 12.66±0.32a |
0 Gy+SP组 | 1 100.65±29.08a | 19.77±0.34a | 12.23±0.22 |
2 Gy+SP组 | 1 174.97±21.75b | 20.34±0.34b | 12.83±0.30 |
6 Gy+SP组 | 1 065.30±40.36c | 25.33±0.34 | 11.85±0.21 |
12 Gy+SP组 | 1 285.55±21.81d | 22.42±0.22d | 13.09±0.18d |
18 Gy+SP组 | 1 317.28±26.13e | 27.64±0.36 | 14.78±0.21e |
F | 112.077** | 114.822** | 36.113** |
Tab. 5 Comparison of protein expression levels of VEGF, bFGF and PDGF between the ten groups
组别 | VEGF | bFGF | PDGF |
---|---|---|---|
0 Gy组 | 788.84±41.15 | 24.92±0.28 | 12.02±0.21 |
2 Gy组 | 856.82±24.47a | 26.90±0.59a | 12.50±0.40a |
6 Gy组 | 954.71±23.71a | 24.75±0.28 | 11.74±0.19 |
12 Gy组 | 1 090.68±15.14a | 25.93±0.27a | 12.18±0.22 |
18 Gy组 | 1 140.53±24.67a | 26.92±0.94a | 12.66±0.32a |
0 Gy+SP组 | 1 100.65±29.08a | 19.77±0.34a | 12.23±0.22 |
2 Gy+SP组 | 1 174.97±21.75b | 20.34±0.34b | 12.83±0.30 |
6 Gy+SP组 | 1 065.30±40.36c | 25.33±0.34 | 11.85±0.21 |
12 Gy+SP组 | 1 285.55±21.81d | 22.42±0.22d | 13.09±0.18d |
18 Gy+SP组 | 1 317.28±26.13e | 27.64±0.36 | 14.78±0.21e |
F | 112.077** | 114.822** | 36.113** |
[1] | 何秀娟, 林燕, 刘青武, 等. 皮肤成纤维细胞在创面愈合中的研究进展[J]. 中华损伤与修复杂志(电子版), 2021, 16(1):74-77. |
HE X J, LIN Y, LIU Q W, et al. Research progress of skin fibroblasts in wound healing[J]. Chin J Injury Repair and Wound Healing, 2021, 16(1):74-77. doi: 10.3877/cma.j.issn.1673-9450.2021.01.015. | |
[2] | 曾令军, 王文军, 李雪森, 等. P物质对人胚肺成纤维细胞作用及机制[J]. 中国公共卫生, 2021, 37(5):849-852. |
ZENG L J, WANG W J, LI X S, et al. Effect of substance P on human embryo lung fibroblasts MRC-5 and its mechanism[J]. Chin J Public Health, 2021, 37(5):849-852. doi: 10.11847/zgggws1127521-new. | |
[3] | FU H D, WANG S, GE B, et al. Nerve growth factor and substance P may be involved in moist exposed burn ointment-mediated chronic refractory wound healing[J]. Exp Ther Med, 2018, 16(3):1987-1993. doi: 10.3892/etm.2018.6390. |
[4] | JUNG N, YU J, UM J, et al. Substance P modulates properties of normal and diabetic dermal fibroblasts[J]. Tissue Eng Regen Med, 2016, 13(2):155-161. doi: 10.1007/s13770-016-9085-2. |
[5] | STUNOVA A, VISTEJNOVA L. Dermal fibroblasts-A heterogeneous population with regulatory function in wound healing[J]. Cytokine Growth Factor Rev, 2018, 39:137-150. doi: 10.1016/j.cytogfr.2018.01.003. |
[6] | 蒋伟, 王正国, 赖西南, 等. P物质对肉芽组织成纤维细胞bFGF表达的调控作用及意义[J]. 中华烧伤杂志, 2003, 19(3):159-162. |
JIANG W, WANG Z G, LAI X N, et al. Regulative effects and significance of substance P on the expression of basic fibroblast growth factor of granulation tissue fibroblasts in vitro[J]. Chin J Burns, 2003, 19(3):159-162. doi: 10.3760/cma.j.issn.1009-2587.2003.03.010. | |
[7] | SALO P, BRAY R, SEERATTAN R, et al. Neuropeptides regulate expression of matrix molecule, growth factor and inflammatory mediator mRNA in explants of normal and healing medial collateral ligament[J]. Regul Pept, 2007, 142(1/2):1-6. doi: 10.1016/j.regpep.2007.01.001. |
[8] | BAINBRIDGE P. Wound healing and the role of fibroblasts[J]. J Wound Care, 2013, 22(8):407-408,410-412. doi: 10.12968/jowc.2013.22.8.407. |
[9] | CAKIN M C, OZDEMIR B, KAYA-DAGISTANLI F, et al. Evaluation of the in vivo wound healing potential of the lipid fraction from activated platelet-rich plasma[J]. Platelets, 2020, 31(4):513-520. doi: 10.1080/09537104.2019.1663805. |
[10] | 何秀娟, 马慧可, 刘青武, 等. 细胞因子在创面修复中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(5):579-585. |
HE X J, MA H K, LIU Q W, et al. Research progress of cytokines in wound healing[J]. Chin J Clin Pharmacol Ther, 2021, 26(5):579-585. doi: 10.12092/j.issn.1009-250.2021.05.015. | |
[11] | TONNESEN M G, FENG X, CLARK R A. Angiogenesis in wound healing[J]. J Investig Dermatol Symp Proc, 2000, 5(1):40-46. doi: 10.1046/j.1087-0024.2000.00014.x. |
[12] | KOMI D, KHOMTCHOUK K, SANTA M P. A review of the contribution of mast cells in wound healing:Involved molecular and cellular mechanisms[J]. Clin Rev Allergy Immunol, 2020, 58(3):298-312. doi: 10.1007/s12016-019-08729-w. |
[13] | KANT V, GOPAL A, KUMAR D, et al. Topically applied substance P enhanced healing of open excision wound in rats[J]. Eur J Pharmacol, 2013,g 715(1/2/3):345-353. doi: 10.1016/j.ejphar.2013.04.042. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||